DNA mucosal HIV vaccine in humans
- PMID: 11885941
- DOI: 10.1016/s0168-1702(01)00396-3
DNA mucosal HIV vaccine in humans
Abstract
This is a demonstration of immune activation by delivery of genetic vaccines in human mucosa. We analyzed the local and systemic responses in HIV-1 infected individuals following intraoral jet-injections of HIV-1 DNA constructs encoding the nef, rev, and tat regulatory genes. The immunological responses of the oral mucosa may be representative of other mucosal sites and was therefore selected for induction of mucosal reactivity by DNA immunization. The oral and intramuscular routes induced specific systemic T cell proliferative responses. Immunohistochemical analysis of oral biopsies 2 days after immunization revealed increased levels of granulocytes and T cells as well as expression of HLA-DR. T cell markers for CD3 +, CD4 + and CD8 + were significantly increased in the vaccinated mucosa. Vaccine-specific local and systemic antibodies were present during the immunization. However, increases were neither seen in the local or systemic titer nor in the B-cell accumulation in response to the immunizations. The presence of HIV-1 plasmid DNA was observed in mucosal biopsies as well as local proinflammatory T lymphocyte immune responses with predominantly IL-2 expression in the oral mucosal transudate.
Similar articles
-
Clarification of how HIV-1 DNA and protein immunizations may be better used to obtain HIV-1-specific mucosal and systemic immunity.Expert Rev Vaccines. 2007 Apr;6(2):203-12. doi: 10.1586/14760584.6.2.203. Expert Rev Vaccines. 2007. PMID: 17408370 Review.
-
Simultaneous approach using systemic, mucosal and transcutaneous routes of immunization for development of protective HIV-1 vaccines.Curr Med Chem. 2011;18(26):3953-62. doi: 10.2174/092986711796957293. Curr Med Chem. 2011. PMID: 21824096
-
Gene combination raises broad human immunodeficiency virus-specific cytotoxicity.Hum Gene Ther. 2001 Sep 1;12(13):1623-37. doi: 10.1089/10430340152528129. Hum Gene Ther. 2001. PMID: 11535166 Clinical Trial.
-
DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8+ T-Cell Responses by Interleukin-12 Plasmid DNA.Clin Vaccine Immunol. 2017 Nov 6;24(11):e00263-17. doi: 10.1128/CVI.00263-17. Print 2017 Nov. Clin Vaccine Immunol. 2017. PMID: 28931520 Free PMC article. Clinical Trial.
-
Mucosal HIV vaccines: where are we now?Curr HIV Res. 2004 Jan;2(1):1-10. doi: 10.2174/1570162043485004. Curr HIV Res. 2004. PMID: 15053336 Review.
Cited by
-
Oral manifestations associated with HIV infection.Curr HIV/AIDS Rep. 2008 Feb;5(1):5-12. doi: 10.1007/s11904-008-0002-8. Curr HIV/AIDS Rep. 2008. PMID: 18417029 Review.
-
Therapeutic immunization for HIV.Springer Semin Immunopathol. 2006 Nov;28(3):221-30. doi: 10.1007/s00281-006-0029-0. Epub 2006 Oct 10. Springer Semin Immunopathol. 2006. PMID: 17031650 Review.
-
Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation.J Virol. 2005 Jun;79(11):7059-67. doi: 10.1128/JVI.79.11.7059-7067.2005. J Virol. 2005. PMID: 15890945 Free PMC article.
-
Polymeric Materials for Gene Delivery and DNA Vaccination.Adv Mater. 2009 Feb 23;21(8):847-867. doi: 10.1002/adma.200801478. Epub 2008 Dec 4. Adv Mater. 2009. PMID: 28413262 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials